Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea, the twins, how are they
I thought your very dangerous "lawyer", aka your nephew or niece, would initiate a discovery? I was happily waiting for this - a discovery offers many advantages.
Where is that?
It's gone? Now it's the "SEC"? LOLOL empty threats
This is how OTC scam stocks like CYDY work: lots of empty promises and empty threats. And nothing to show for it. Until the stock reaches $0.0001
Lets see how the Sec will feel , me investing lot of my money , losing a lot right now , in the drug which saved my son live , and even before, a drug I was a believer ,
Or you trying to manipulate the market , posting for weeks that your twins were damage by leronlimab
I cant wait , let them investigate both of us ,!!!!!!!!!!!!!!!!!!!!!!!!!!!
Maybe we will ALL learn , How really are your twins..and what happened with my son !!!!!
I cant wait !!!
All imo.
GLTA longs
You took actively part in a financial fraud.
No heroism. The opposite. Scamming innocent investors to pump the warrants you purchased with a sweet deal you refused to disclose to them.
That’s sadly how many OTC scams operate.
Take care of your twins since leronlimab damage them seriously per your many posts ,
I hope they feeling better ...
GLTA longs..!!!
I don't trade , I invest . And here I invested in a drug ..
I don't trade , I invest . And here I invested in a drug ..
And some of you coming making stupid comment not even knowing MOA ( mode of action ) of this drug ..is really almost a joke ..
This drug saved my son life in August of 2021 , with severe/critical Covid -Delta , when everything else failed,
and you all should be hoping it is approved , so ALL may benefit.
The worst is when some "EXPERTS " coming , not knowing anything about the drug , but bashing , I guess for different reasons , some for money , and others for whatever..
I am here since January of 2016 , and I never saw drug like this one , and without one serious side effect.
You ALL , including Janice Shell , should be fighting for approval of this drug , and not bashing.
But because of people as some of you , good drugs are not approved for us.
Great job , congratulation!!!!
All imo.
GLTA longs
Lol .. yes you educated me a bit here. Thank you for that.
You’re also right I shouldn’t of put the or in there she could be both.
I’ve battled her on numerous tickers. Never worked out for me. Hope it does here for you. Good luck. Take care.
Wow I hit a nerve. For the record I have literally no skin in this game. I watch this ticker from time to time cause of a buddy who’s long and been in it for years probably longer than yourself.
And no it’s never good when she shows up sorry to tell ya. There’s been red flags with this thing for years. Hard to see when you are long. I’ve been in your shoes before bud that’s why I don’t trade otc anymore.
Good luck to everyone make that $$ if you can.
" You would be , if you actually had to do that, But I jest : you'd be long dead "
You are right Janice , I rather be dead then do what you , and few others here doing..
Go leronlimab..!!!!!!!!
all imo.
GLTA longs.
Whoa.... stopped to take a peak and WOW!
Looks like we're "knee-deep in the AYCE* club!"
They can cast aspersions
But Leronlimab's MOA (mechanism of action) and lack of "nasty " (so far) side-effects
Makes it (IMO) >>> "Golden"
And ...
First - BP KNOWS >> of Leronlimab's existence/potential mega-billion money maker [in their hands]/BUT potential SUBSTANTIAL threat to their drug lines if allowed to exist.
And a round of applause for the AYCE club spending their timmmmmmmmmmmmme here!
(Muffled applause dwindles out)
(and guess who supports the "AYCE-club presence" DUH!)
But sooner or later
There's "gonna be a 'leak in the dike" and the brotherhood/sisterhood of Big Pharma is going to 'fracture viciously as different entities spring to secure the profitable rights/licenses to Leronlimab's numerous applications both as a primary agent and as an adjuvant ( greatly multiplying potential applications).
Like tossing bloody meat into the piranha pool, LOL.
And...how far away is the moment?
the Juicy,pink meat
splashes in?
6mo? a year? 18mos? (the brotherhood of pharma is only annual report deeeeeeep.)
Some repugnant lawsuits and poor earnings could initiate a need for
Solidifying future income - the "new-big-hitter" on the drug-lineup.
>>...and then the fun begins.
Except
Very unfortunately,
the "AYCE club" will be
"pounding the pavement."
(Funny thought - many of them might be significant holders of shares - they're here all day, get to see some convincing info, and certainly track issue better than I can...
Hmmmm, maybe they're walking away with big smiles.
IRONY
IMO
*AYCE = acronym for All You Can Eat.
All of the above all the above all the above like a song you said it!!!!!!!!!!!!!!
Yo why are you so mad relax damn
Probably FB Borgen will appeal FDA`s decision.
WTF?? Borgers was shut down by the SEC. Do you really believe you can make sound investment decisions without realizing the FDA and the SEC are the same agency?
And Borgers won't appeal anything. It agree to settle, and pay $12 million.
And I don't need to bash day and night to make a living , I rather be starving !!
You would be, if you actually had to do that. But I jest: you'd be long dead.
Do you realize you are also a nobody?
“Either she’s the best shorter of all time or she actually knows what she’s talking about. I imagine the later.”
Latter. I know what you meant though.
False dilemma?
What if she’s both?
Neither?
I find it offensive that you seem to think shorts can’t be good at what they do while also knowing what it is they speak of.
She’s either the best short OR knows what she’s talking about?
Janice thanked you, so she is apparently cool with the possibility of being the best lying short who doesn’t know what she’s talking about.
Maryj55555 is either a moron or a maroon.
Another false dilemma.
Bring back D. All of the above.
janit shell, I read the companies filings that you mentioned and assumed, that Borgens are guilty. Then I read the letter from F B Borgen, stating "wether it agrees with the above disclosure" from the FDA has not been included in this report.
Probably FB Borgen will appeal FDA`s decision. Did the FDA notified publicly that they changed the regulations, then probably a jury will decide. Just my opinion.
" Beware when she show up "
What is your point .
Are you scarring us here ..??????
Janice Shell show up , you are done , you are saying ,
are you another of her associate who came here ?? Not the first one , I am sure it wont be the last..
Sorry . It is not that easy .
Yes , company itself going through a difficult times .
But the drug is like no other .
I will be happy to debate Janice here in public about our drug , but she said that she knows nothing about it , or something like that she said !!!
How easy you are impressed , if Janice who put over 300,000 posts since 2001 , attacking companies in trouble is impressing you
. But like in CYDY she has no idea about the products .
I don’t know if CYDY will succeed , but what I know for sure , leronlimab is a drug like no other .
And I don't need to bash day and night to make a living , I rather be starving !!
And you so impressed ???
So how she is good ???? When she is posting about a company with one drug , and she has no idea what this drug is representing .
Really very sad what people doing for money ..
All imo
GLTA longs
What I forgot to do since I started posting again, to thank Investorshub to let me do it without charge.
Although, I mentioned misiu143, the most active poster for upholding Lironlimab, my favorite drug, and wont to include every one else to keep Lironlimab alive in their posts, to thank them.
And thank you to two nobodies!
Yada yada yada.
I hated Janice for a long time … until I realized I was on the wrong side of things. Beware when she shows up it’s never good. Either she’s the best shorter of all time or she actually knows what she’s talking about. I imagine the later.
I have a beautiful woman waiting for a dance, last post for tonight, but if I have a chance tomorrow in my schedule, will post the difference in a leech and a parasite, or if there is a difference relating to leronlimab, Wishing all a blessed night and sweet dreams!
I just pointed you to three new SEC filings. What is your problem? Do you know anything at all about this stuff?
Rhetorical question, of course.
The leech auditor bullshit involves approximately 500 companies, must have hit a nerve, I have a life, maybe y’all should try to find one instead of leeching a .15 company, thanks for the cheap shares, time for happy hour, Dr Jay the Rock star, 100% , awesomeness, pure and loving it!
Just astonishing. The company put out a an announcement of the dismissal of Borgers, and is own need to find a new auditor, and all the lot of you can do is babble about "bashers", There's a total of three filings.
https://www.sec.gov/Archives/edgar/data/1175680/000155837024006814/cydy-20240506x8k.htm
https://www.sec.gov/Archives/edgar/data/1175680/000155837024006815/cydy-20240506x424b3.htm
https://www.sec.gov/Archives/edgar/data/1175680/000155837024006816/cydy-20240506x424b3.htm
As soon as he cashes in the $400k they owe him, he’ll be high-stepping it outta there!
Then the next pigeon will be hailed at the Chosen One! Pure comedy
Leeches will leech until their neck is broke, sick but entertaining, however they helped with the accumulation, Dr Jay is the true rock star that will bring it home, 100%
poor angry little basher..I get it, things are bad for you.
Cydy longs are so unbelievably stupid
Ditch diggers are pathetic. How's that for the working man idiot
"With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19.”
FDA's words not mine. Guess you're calling the FDA a fraud. Hmm lawyers will enjoy that post!!!!!! See I can do it too! Moron.
Another wannabe! Nothing is happening but the dissolution of this scam.
When you’re ever correct for the first time, come back.
I bet a ditch digger at prevailing wages makes a heck of alot more than you do, way to put down the working man! We all know why you're here along with the rest of the clown show, got news for you, there's a lot coming down the pike that will probably hurt you and the others financially- good luck!
Another genius. Intraday highs are not the same as where it ends.
Yet, here are you mullets defending the worse investment ever. You’d be better setting your money on fire to avoid the embarrassment
Be honest, how often does your family say: “are we rich yet?” and you sheepishly have to explain how you’ve lost 90% of it! So funny!
There’s always community college and ditch digging.
"Bet you got excited to see $.15 today! LOL
Only $.14 from zero."
Nice math skills, dummy.
Great point!
Now tell the upticks from FDA hold-lift and Jay taking CEO job permanently
Well played!
So the leeches audit company bullshit didn’t seem to work today, maybe a new leech twist tomorrow, this board is entertaining to say the least, carry on, lol !!
Call your lawyer and cry to them.
You can’t debate me… it’s not a fair competition. I actually pity you. Carry on…. Soon enough this clown car will be completely derailed
Continue on crying about people insulting you while you’re hurling insults! That’s why you’re fraud and a liar.
I do want to debate you , my problem is you are very aggressive and insulting , I never met people in my life like few of you here ..
Your accusation are really strong , not even sure if legally you can accuse people you don’t know of illegal transactions !!!!!!!! .
Is that your opinion , or is this a fact ????
And yes , I posted every drug one by one my son was on , and when he started to improve . And there is no question in anyone who watched my son what saved his life
It was leronlimab !!!!
So just stop attacking me ..go make your money some other way , maybe playing a clown ????
Thank you ..
Have a good day ..
All imo
GLTA longs
That's obviously your idiotic opinion. But legally it's called fraud.
We bring truth. You bring bullshit! Nothing ever seems to go your way. Ever wonder why?
Bet you got excited to see $.15 today! LOL
Only $.14 from zero. I’ll trust my DD over yours any day.
You conflate too many issues which is why I can’t take you seriously nor does anyone who actually calls out the DD on this.
Did I pray for you son? Yes
Do I believe LL saved him? NO! You fail to mention the other treatments he received so YOU don’t know! Just be thankful he survived, like my dad did who has COPD and didn’t get LL! So in a two person study, one with comorbidity risk survived without LL… hmm
You received warrants. You called the CEO on his cell phone to get LL when others couldn’t get it and you had a poster with financial interest write an article that WAS PAID TO PRINT? No empirical data
You don’t want to debate me! Outside of conspiracy theories and cultish blindness, you’ve been wrong EVERY step of the way!
"What happened to your kind heart lately ..????"
Money happened. He/She is only here to make his money by promoting negative sentiment for this stock. That is the only reason he/she has been here for the last few years. Now he/she is just like the rest of the bashers. They bring nothing to the board.
The assertion wasn’t toward you but the charlatan you reference! That’s not opinion but rather documented fact, courtesy of said poster being ignorant enough to post it
It is so sad what you said here ..
" Getting sweetheart deal on warrants"
Wow , they were offered to EVERY shareholder by the company , now Paulson is offering to everyone , why not to go with them , if you think they are extra deals , and maybe they are .., they are available to all .. go for it !!!
As for a drug for my dying at the time son,
Over 100 patients were treated by compassionate or RTT with leronlimab , not ONLY my son . , I still remember when you posted , you praying for my son !!!
What happened to your kind heart lately ??
And I did the article to show to people who didn’t know , we don’t need to die , just ask for leronlimab !!
All imo.
GLTA longs.
Grip it and Sip it, I answer this, misui143 can do it later, since I know misui only from this message board, altho I would like to know her closer.
You are wasting my time with your accusation.
I do not know the ceo of CytoDyn and I never called him, but I sent a letter to him a couple month ago but got no answer.
My trading only goes through my trading company. I should not even go that low to explain to you.
Followers
|
811
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
233354
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |